InvestorsHub Logo
Followers 75
Posts 7486
Boards Moderated 0
Alias Born 04/18/2006

Re: None

Wednesday, 05/26/2021 4:44:54 PM

Wednesday, May 26, 2021 4:44:54 PM

Post# of 194833
Pharmacy Hot Info

Hot topics from April

HRSA 340B update
This week brought another significant milestone to the 340B program. The program's governing body, Health Resources and Services Administration (HRSA), sent letters to the following six pharmaceutical manufacturers stating that the restrictions these manufacturers placed on 340B program pricing to covered entities dispensing medications through contracted pharmacies has resulted in overcharges in direct violation of the 340B statute:
• AstraZeneca
• Eli Lilly
• Novartis
• Novo Nordisk
• Sanofi
• United Therapeutics

HRSA has requested a response by June 1 from these organizations as well as a plan on how they would provide these overcharges back to the covered entities that were impacted.

This is a link HRSA 340B to a brief overview of key recommendations that our members can follow related to this latest action.


"To Give Anything Less Than Your Best, Is To Sacrifice the Gift." - Steve Prefontaine

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent RXMD News